Serving customers in the clinical, research, and applied markets, Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, and beyond. By empowering large-scale analysis of genetic variation and function, Illumina is enabling studies that were not imaginable just a few years ago.